November 16, 2015
A California federal court's decision for drugmakers in multidistrict litigation over their alleged failure to warn of their Type 2 diabetes drugs' potential to cause pancreas problems is among the first to clarify in detail that the U.S. Food and Drug Administration need not explicitly reject a heightened warning in order for branded-drug companies to beat labeling claims by injured patients.
November 09, 2015
Drugmakers including Merck defeated state law claims in multidistrict litigation accusing the companies of failing to warn patients of pancreas problems from Type 2 diabetes drugs when a California federal judge ruled Monday the U.S. Food and Drug Administration would have rejected the warnings on labels.
January 21, 2015
Drugmakers including Eli Lilly & Co. argued Tuesday that the plaintiffs in multidistrict litigation over the alleged pancreatic risks of their diabetes drugs had violated a confidentiality order by showing confidential company documents to their expert, the chairman of what they claim is a competing pharmaceutical company.
October 07, 2014
A California federal judge on Monday refused to force Eli Lilly and Co., Novo Nordisk Inc. and other drugmakers to turn over documents concerning pancreatic cancer events to plaintiffs in multidistrict litigation over diabetes drugs, ruling that the materials aren't relevant to the central disputes in the case.
August 27, 2014
Eli Lilly and Co., Novo Nordisk Inc. and other drug manufacturers urged a California federal court on Tuesday not to force them to produce documents related to pancreatic cancer events in multidistrict litigation over diabetes drugs, calling the request an "unreasonably burdensome fishing expedition."
February 27, 2014
The U.S. Food and Drug Administration and European Medicines Agency found no firm evidence Thursday that diabetes drugs made by Merck & Co. Inc., Novo Nordisk Inc. and others cause pancreatic cancer, as plaintiffs allege in multidistrict litigation against the drugmakers in California.